Financial News Feed

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Misonix, Inc. (NASDAQ: MSON ) Repligen Corporation (NASDAQ: RGEN ) Uniqure NV (NASDAQ: QURE ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on June 5) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) ChemoCentryx Inc (NASDAQ: CCXI )(moved in sympathy with its rival, which has a competing drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Harvard Bioscience, Inc....

Read more

ACRS earnings call for the period ending March 31, 2019....

Read more

Daily Insider Ratings Round Up 5/13/19
09:18pm, Wednesday, 15'th May 2019
No summary available....

Read more

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2019 Earnings Conference Call May 08, 2019 05:00 PM ET Company Participants Kamil Ali-Jackson - Chief Legal Officer...

Read more

Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

Read more

No summary available....

Read more

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most recent earnings release Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) announced in December 201…...

Read more

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news....

Read more

WAYNE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for ATI-450, an oral MK2 inhibitor, for the treatment of rheumatoid arthritis (RA). If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 clinical trial of ATI-450 in the second half of 2019. "We are very pleased to have this IND under review by the FDA," said Dr. Neal Walker, President & Chief Executive Officer of Aclaris. "We look forward to beginning the development of ATI-450 as a potential treatment for rheumatoid arthritis and other potential indications driven by TNFα, IL-1β, IL-6, or IL-8. We believe there is an important need to provide additional treatment options for rheumatoid arthritis to improve overall patient care." ATI-450, an investigational medicine formerly known as CDD-450, would be the first novel compound created by Confluence Discovery Technologies, Inc., our indirect wholly owned subsidiary, to enter the clinical phase of development....

Read more

Aclaris nabs new ruxolitinib patent
11:26am, Wednesday, 24'th Apr 2019
The USPTO issues U.S. Patent No. 10,265,258 to Aclaris Therapeutics (ACRS) covering methods of treating alopecia areata ((AA)) using ruxolitinib or its iso...

Read more

Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,265,258 covering methods of treating alopecia areata (AA) using...

Read more

Today we are spotlighting shares of Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) and looking at how the firm stacks up in terms of valuation by the numbers. One of the most important ratios to look at w...

Read more

Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Monday, ValuEngine reports. A number of other br...

Read more

In trying to determine the current valuation of Kanto Denka Kogyo Co., Ltd. (TSE:4047) shares, we note that the Book to Market ratio of the shares stands at 0.943779. It’s commonly accepted that a B...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank